Repligen Stock Price, News & Analysis (NASDAQ:RGEN) $159.27 -2.60 (-1.61%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$158.33▼$164.7150-Day Range$114.17▼$164.9452-Week Range$110.45▼$200.98Volume472,497 shsAverage Volume541,630 shsMarket Capitalization$8.89 billionP/E Ratio78.46Dividend YieldN/APrice Target$189.55 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Repligen MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.82 Rating ScoreUpside/Downside19.0% Upside$189.55 Price TargetShort InterestBearish11.54% of Float Sold ShortDividend StrengthN/ASustainability-1.33Upright™ Environmental ScoreNews Sentiment0.71Based on 15 Articles This WeekInsider TradingSelling Shares$557,328 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.44 out of 5 starsMedical Sector156th out of 942 stocksBiological Products, Except Diagnostic Industry24th out of 161 stocks 3.4 Analyst's Opinion Consensus RatingRepligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $189.55, Repligen has a forecasted upside of 19.0% from its current price of $159.27.Amount of Analyst CoverageRepligen has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.54% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Repligen has recently increased by 0.34%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRepligen does not currently pay a dividend.Dividend GrowthRepligen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRepligen has received a 68.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Spin filters", "Protein gels", and "Chromatography columns" products. See details.Environmental SustainabilityThe Environmental Impact score for Repligen is -1.33. Previous Next 3.7 News and Social Media Coverage News SentimentRepligen has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Repligen this week, compared to 4 articles on an average week.Search Interest2 people have searched for RGEN on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Repligen to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Repligen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $557,328.00 in company stock.Percentage Held by InsidersOnly 1.10% of the stock of Repligen is held by insiders.Percentage Held by Institutions97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Repligen are expected to remain at $1.72 per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repligen is 78.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 110.76.Price to Earnings Ratio vs. SectorThe P/E ratio of Repligen is 78.46, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 82.19.Price to Earnings Growth RatioRepligen has a PEG Ratio of 3.93. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRepligen has a P/B Ratio of 4.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Repligen Stock (NASDAQ:RGEN)Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.Read More RGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGEN Stock News HeadlinesDecember 9, 2023 | americanbankingnews.comRepligen Co. (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by AnalystsDecember 7, 2023 | finance.yahoo.comRepligen's (NASDAQ:RGEN) investors will be pleased with their impressive 158% return over the last five yearsDecember 9, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.December 7, 2023 | finance.yahoo.comRepligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription AgreementsDecember 6, 2023 | americanbankingnews.comBenchmark Downgrades Repligen (NASDAQ:RGEN) to HoldDecember 5, 2023 | msn.comBenchmark Downgrades Repligen (RGEN)December 4, 2023 | realmoney.thestreet.comRepligen downgraded to Hold from Buy at BenchmarkDecember 4, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for RepligenDecember 9, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comDecember 1, 2023 | americanbankingnews.comCritical Comparison: Repligen (NASDAQ:RGEN) versus Gene Biotherapeutics (OTCMKTS:CRXM)November 26, 2023 | investing.comRepligen (RGEN) Earnings Dates & ReportsNovember 15, 2023 | finance.yahoo.comDoes Repligen Corp. (RGEN) Have a Bright Future?November 14, 2023 | benzinga.comUPDATE – Repligen Announces Publication of the Company's 2022 Sustainability ReportNovember 14, 2023 | finance.yahoo.comUPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability ReportNovember 14, 2023 | finance.yahoo.comRepligen Announces Publication of the Company’s 2022 Sustainability ReportNovember 7, 2023 | markets.businessinsider.comRobust Sales Growth and Undervalued Potential: Buy Rating on Repligen Despite Market HeadwindsNovember 2, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Eli Lilly & Co (LLY) and Repligen (RGEN)November 2, 2023 | markets.businessinsider.comAnalyst Expectations for Repligen's FutureNovember 2, 2023 | finance.yahoo.comRepligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF DeviceNovember 2, 2023 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Repligen (RGEN)November 1, 2023 | markets.businessinsider.comKeybanc Maintains Overweight Rating for Repligen: Here's What You Need To KnowNovember 1, 2023 | finance.yahoo.comRepligen (RGEN) Shares Rise on Q3 Earnings & Revenue BeatNovember 1, 2023 | finance.yahoo.comRepligen Corporation (NASDAQ:RGEN) Q3 2023 Earnings Call TranscriptNovember 1, 2023 | finance.yahoo.comQ3 2023 Repligen Corp Earnings CallOctober 31, 2023 | sfgate.comRepligen: Q3 Earnings SnapshotOctober 31, 2023 | finanznachrichten.deRepligen Corporation: Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial GuidanceOctober 31, 2023 | benzinga.comA Preview Of Repligen's EarningsSee More Headlines Receive RGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/31/2023Today12/09/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical Instruments & Supplies Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:RGEN CUSIP75991610 CIK730272 Webwww.repligen.com Phone(781) 250-0111Fax781-250-0115Employees2,025Year Founded1981Price Target and Rating Average Stock Price Target$189.55 High Stock Price Target$210.00 Low Stock Price Target$165.00 Potential Upside/Downside+19.0%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$2.03 Trailing P/E Ratio78.46 Forward P/E Ratio92.60 P/E Growth4Net Income$185.96 million Net Margins17.29% Pretax Margin18.79% Return on Equity6.08% Return on Assets4.69% Debt Debt-to-Equity RatioN/A Current Ratio2.69 Quick Ratio2.11 Sales & Book Value Annual Sales$669.78 million Price / Sales13.28 Cash Flow$4.20 per share Price / Cash Flow37.94 Book Value$34.41 per share Price / Book4.63Miscellaneous Outstanding Shares55,832,000Free Float55,218,000Market Cap$8.89 billion OptionableOptionable Beta1.08 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Anthony J. Hunt (Age 59)CEO & Director Comp: $1.59MMr. James R. Bylund (Age 59)Chief Operating Officer Comp: $820.26kMs. Christine Gebski (Age 54)Senior Vice President of Filtration & Chromatography Comp: $625.76kMr. Ralf Kuriyel (Age 64)Senior Vice President of Research & Development Comp: $661.75kMr. Olivier LoeillotPresident & Chief Commercial OfficerMr. Jason K. Garland (Age 49)Chief Financial Officer Mr. Keith Lee RobinsonChief Information OfficerMs. Sondra S. NewmanGlobal Head of Investor RelationsMs. Kimberly A. CornwellGeneral CounselDr. Jaime M. Humara Ph.D.Senior Vice President of MarketingMore ExecutivesKey CompetitorsAptarGroupNYSE:ATRVerona PharmaNASDAQ:VRNAChemedNYSE:CHEPenumbraNYSE:PENMedpaceNASDAQ:MEDPView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 29,215 shares on 12/1/2023Ownership: 2.502%B. Riley Wealth Advisors Inc.Sold 133 shares on 12/1/2023Ownership: 0.003%American Century Companies Inc.Bought 107,570 shares on 11/30/2023Ownership: 0.390%Banque Pictet & Cie SABought 11,247 shares on 11/27/2023Ownership: 0.056%Walleye Capital LLCBought 4,800 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions RGEN Stock Analysis - Frequently Asked Questions Should I buy or sell Repligen stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RGEN shares. View RGEN analyst ratings or view top-rated stocks. What is Repligen's stock price target for 2024? 11 equities research analysts have issued 1 year target prices for Repligen's shares. Their RGEN share price targets range from $165.00 to $210.00. On average, they anticipate the company's stock price to reach $189.55 in the next year. This suggests a possible upside of 19.0% from the stock's current price. View analysts price targets for RGEN or view top-rated stocks among Wall Street analysts. How have RGEN shares performed in 2023? Repligen's stock was trading at $169.31 at the start of the year. Since then, RGEN stock has decreased by 5.9% and is now trading at $159.27. View the best growth stocks for 2023 here. When is Repligen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024. View our RGEN earnings forecast. How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) announced its quarterly earnings data on Tuesday, October, 31st. The biotechnology company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.14 by $0.09. The biotechnology company earned $141.20 million during the quarter, compared to analysts' expectations of $140.68 million. Repligen had a net margin of 17.29% and a trailing twelve-month return on equity of 6.08%. Repligen's revenue for the quarter was down 29.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.77 earnings per share. What ETFs hold Repligen's stock? ETFs with the largest weight of Repligen (NASDAQ:RGEN) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Invesco Biotechnology & Genome ETF (PBE), BlackRock Future Innovators ETF (BFTR), Fidelity Disruptive Medicine ETF (FMED), VanEck Biotech ETF (BBH), Nuveen ESG Mid-Cap Growth ETF (NUMG), BNY Mellon Innovators ETF (BKIV) and Invesco ESG NASDAQ Next Gen 100 ETF (QQJG). What guidance has Repligen issued on next quarter's earnings? Repligen issued an update on its FY23 earnings guidance on Tuesday, October, 31st. The company provided EPS guidance of $1.70-1.76 for the period, compared to the consensus earnings per share estimate of $1.74. The company issued revenue guidance of $635-645 million, compared to the consensus revenue estimate of $644.49 million. What is Tony J. Hunt's approval rating as Repligen's CEO? 13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW). Who are Repligen's major shareholders? Repligen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sands Capital Management LLC (2.81%), Artisan Partners Limited Partnership (2.79%), Wellington Management Group LLP (2.50%), Bank of New York Mellon Corp (2.14%), Ameriprise Financial Inc. (2.07%) and Impax Asset Management Group plc (1.74%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr. View institutional ownership trends. How do I buy shares of Repligen? Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Repligen have any subsidiaries? The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.Read More This page (NASDAQ:RGEN) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.